Future attacks remain a very real threat. Yet, we are still using the same anthrax vaccine that was developed 40 years a...
We have to sort of think about what are the priority areas, knowing full well that we can't guarantee absolute, 100-perc...
I'd like to start thinking about it now, and looking at it.
I think we need to think about priorities.
We know flu is here... we know there are a lot of other strains of flu out there.
It's got great bipartisan support. It's being held up a little bit, but it's going to pass.
What we can do, if we properly fund these programs, and manage them, Mr. Chairman, vice chairman, we can push the decima...
I think now's time to take stock and think, on the reauthorization, do we need to do some realignment here?
BARDA would be the purchaser, but this fund would be the investor.
The fact that we were using 60-year-old technologies to make important vaccines like H1N1 was one of the reasons that Se...
For all that we put on their plate.
And thank all of you for your testimonies, and for your work in this field, and your leadership in this field.
It's sometimes said that, while the Defense Appropriations Subcommittee defends America, this subcommittee actually defi...
Despite all those improvements, a continuing vulnerability is our dependence on egg-based technology to produce influenz...
I'm not going to sign off on it. That's $200 million.
Is anthrax the major threat that we have that we should be worried about with regard to bioterrorism?
I mean, it's just--it's just very difficult to do that, okay? It's just difficult.
Now, that's a good idea. I like that.
